SkyePharma names new CFO
This article was originally published in Scrip
SkyePharma has named Andrew Derodra chief financial officer and executive director – effective from the fourth quarter 2013. Mr Derodra joins from UK-based, multinational agribusiness Tate & Lyle, where he has been group vice-president of finance and control since 2011. He succeeds Peter Grant, who was appointed chief executive officer of SkyePharma in January 2012 but retained responsibility for the company's financial affairs.
You may also be interested in...
The stereotypical view of an Alzheimer’s patient as an elderly person needs to change and interventions made earlier in the disease course, while we wait for novel drug therapies, said experts at a recent virtual meeting.
A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June.
Experts discuss the future of brain health, changing the stereotypical view of an Alzheimer’s patient and how technology and science have evolved the treatment possibilities for dementia patients in 2020 – even if ‘clinical practice is taking a long time to catch up.’